DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Azelastine hydrochloride, 922, 922t
for ophthalmic use, 1789
AZELEX (azelaic acid), 1817, 1830
Azithromycin
for chancroid, 1842t
for Chlamydia, 1842t
for non-gonococcal urethritis, 1842t
for ophthalmic use, 1781t
pharmacokinetics of, 1816t
volume distribution, 1816t
Azlocillin, 1484
Azoles
arrhythmias caused by, 832
for cutaneous fungal infection, 1818
indications for, 1816t
and statins, interactions, 896
AZOPT (brinzolamide), 680
B
Babesiosis, 1423
Bacillus Calmette-Guérin (BCG), 1022
Bacitracin, 1543–1544
prophylaxis, for superficial
infections, 1817
Baclofen, pharmacokinetics of, 1816t
Bacteria, susceptibility testing in,
1369–1370
Bacterial endocarditis, gentamicin for,
1515–1516
Bacterial infections, of skin, 1817
Bacterial vaginosis, 1842t
BACTRIM (trimethoprimsulfamethoxazole),
1817
BACTROBAN (mupirocin), 1817
Balantidiasis, 1423
Baldness
female pattern, 1829–1830
male pattern, 1829–1830
Barbiturates
absorption, fate, and excretion of, 473
abuse and addiction to, 472
addiction, 657
as anesthetics, 539–540
cardiovascular system and, 472
central nervous system and,
469–472
chemistry of, 469
as dose-dependent toxicity, 75
for epilepsy, 593–594
gastrointestinal tract and, 472–473
liver and, 472–473
peripheral nervous structures and,
472
pharmacological properties of,
469–473
Barbiturates (Cont.):
poisoning, 474
respiration and, 472
sleep and, 472
therapeutic uses of, 473–474
tolerance to, 472
Bare lymphocyte syndrome, 104t
Baroreceptors, intrarenal, and renin
release, 722, 723f, 724
Bartter’s syndrome, 947–948
Bartter syndrome, 972
Basal cell carcinoma (BCC)
5-fluorouracil for, 1821
imiquimod for, 1823
Base(s), organic, secretion in proximal
tubule, 676f
Basophils, increased proliferation of,
histamine and, 915
BAY 58-2667, 808
Bayh-Dole Act, 12
BBB. See Blood-brain barrier (BBB)
B cell targeting, 1019
BCG. See Bacillus Calmette-Guérin
(BCG)
BCR-ABL kinase, inhibitors,
1732–1734. See also
Dasatinib; Imatinib
mesylate; Nilotinib
resistance, mechanisms of,
1732–1733, 1733f
BCRP. See Breast cancer resistance
protein (BCRP)
Bed bugs, 1818
Behavior, dopamine and,
356–357
Behçet’s disease
azathioprine for, 1821
cyclophosphamide for, 1821
dapsone for, 1823
tacrolimus for, 1822
thalidomide for, 1824
Belladonna alkaloids, 226. See also
Atropine; Scopolamine
Bemotrizinol, 1827
BENADRYL (diphenhydramine), 1816
BENADRYL (diphenhydramine
hydrochloride), 921t
Benazepril
as antihypertensive agent, 774t,
784–785
clinical pharmacology of, 733
structure of, 732f
Bendroflumethiazide
pharmacology of, 688t
structure, 688t
BENICAR (olmesartan medoxomil), 745
Benign prostatic hyperplasia (BPH),
alpha-adrenergic receptor
antagonists for, 308
BENOQUIN (monobenzone), 1830
BENSAL HP (antifungal combination),
1817
BENZACLIN (antibiotic-benzoyl
peroxide combination), 1817
Benzathine penicillin, for syphilis,
1842t
Benzbromarone, 999–1000
Benzimidazoles
absorption, fate, and excretion of,
1450–1451
anthelmintic action of, 1450
in children, 1453
history of, 1449–1450
precautions and contraindications
with, 1452–1453
in pregnancy, 1452–1453
toxicity and side effects of,
1452–1453
Benznidazole, 1431–1432
Benzocaine, 138t
for pruritus, 1828t
Benzodiazepine-receptor agonists,
novel, 467–469
Benzodiazepines
absorption, fate, and excretion of,
463–465
addiction to, 656–657
adverse psychological effects, 465
as anesthetic adjunct, 552–553
antidote for, 86t
as antiepileptics, 598–599
central nervous system and, 460
chemistry of, 458, 459t
for nausea and vomiting, 1345–1346
pharmacological properties of,
458–465
for pruritus, 1828t
sleep and, 460–461
therapeutic uses of, 465–467, 466t
tolerance to, 460
Benzoic acid, 1589
Benzothiadiazides, 686
Benzothiadiazines (thiazide diuretics),
as antihypertensive agents,
775–777
Benzothiazepines, 102t
Benzothiazipines, 761
Benzoyl peroxide, for acne, 1817
interactions with tretinoin, 1810
Benzphetamine, structure of, 279t
2003
INDEX